Imma Danés

Head of Section

Hospital Universitari Vall d'Hebron

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Imma Danés is the Head of Section at Vall d'Hebron Hospital Universitari, Spain. Her research focuses on the effectiveness and safety of treatments for hypercholesterolemia, drug reimbursement policies for orphan drugs, and adverse drug reactions, particularly in pediatric oncohematology. Recent publications highlight her expertise in clinical pharmacology and patient safety during the COVID-19 pandemic.

Articles (12)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Kristopher Amaro Hosey

Professor associat

Universitat Autònoma de Barcelona Facultat de Medicina

SPAIN

View details

Antònia Agustí

Universitat Autònoma de Barcelona (UAB)

SPAIN

View details

Jaume Mestre Torres

Associate Professor.

Universitat Autònoma de Barcelona Facultat de Medicina

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Imma Danés

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Réplica a la carta al editor de Fernández-Fernández et al. titulada «Efectividad de alirocumab y evolocumab (PCSK9i) en el tratamiento de la hipercolesterolemia» en relación con el artículo publicado por Bosch et al. (Medicina Clínica 2024;163:317-322)

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk

Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review

Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study

Adverse Drug Reactions in Pediatric Oncohematology: A Systematic Review

Spontaneously Reported Adverse Drug Reactions and Their Description in Hospital Discharge Reports: A Retrospective Study

Withdrawal of hospital outpatient treatments in severe diseases due to unacceptable toxicity: A retrospective study from the register of patients and treatments

Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study

Liver, Renal, and Cardiovascular Failure After Unintentional Overdose of Tizanidine in a 2-Year-Old Child

Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service

A case series of confusional states and other neurotoxic effects caused by ertapenem

Collaborators (3)

Kristopher Amaro Hosey

Antònia Agustí

Jaume Mestre Torres

Make your next move.